{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T16:13:11Z","timestamp":1790179991080,"version":"4.1.0"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2020,8,12]],"date-time":"2020-08-12T00:00:00Z","timestamp":1597190400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,8,12]],"date-time":"2020-08-12T00:00:00Z","timestamp":1597190400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Pharmacokinet"],"published-print":{"date-parts":[[2020,12]]},"DOI":"10.1007\/s40262-020-00931-w","type":"journal-article","created":{"date-parts":[[2020,8,12]],"date-time":"2020-08-12T06:02:35Z","timestamp":1597212155000},"page":"1493-1500","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":69,"title":["The Interplay Between Liver First-Pass Effect and Lymphatic Absorption of Cannabidiol and Its Implications for Cannabidiol Oral Formulations"],"prefix":"10.1007","volume":"59","author":[{"given":"Valentina","family":"Franco","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pavel","family":"Gershkovich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilio","family":"Perucca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2046-4171","authenticated-orcid":false,"given":"Meir","family":"Bialer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,8,12]]},"reference":[{"key":"931_CR1","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.ejps.2019.04.003","volume":"134","author":"M Koziolek","year":"2019","unstructured":"Koziolek M, Alcaro S, Augustijns P, Basit AW, Grimm M, Hens B, et al. The mechanisms of pharmacokinetic food\u2013drug interactions: a perspective from the UNGAP group. Eur J Pharm Sci. 2019;134:31\u201359.","journal-title":"Eur J Pharm Sci"},{"issue":"3","key":"931_CR2","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1038\/nrd2197","volume":"6","author":"CJ Porter","year":"2007","unstructured":"Porter CJ, Trevaskis NL, Charman WN. Lipids and lipid-based formulations: optimizing the oral delivery of lipophilic drugs. Nat Rev Drug Discov. 2007;6(3):231\u201348.","journal-title":"Nat Rev Drug Discov"},{"issue":"6","key":"931_CR3","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1007\/BF02537404","volume":"19","author":"A Vost","year":"1984","unstructured":"Vost A, Maclean N. Hydrocarbon transport in chylomicrons and high-density lipoproteins in rat. Lipids. 1984;19(6):423\u201335.","journal-title":"Lipids"},{"issue":"1\u20132","key":"931_CR4","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/S0169-409X(01)00147-8","volume":"50","author":"BK Nordskog","year":"2001","unstructured":"Nordskog BK, Phan CT, Nutting DF, Tso P. An examination of the factors affecting intestinal lymphatic transport of dietary lipids. Adv Drug Deliv Rev. 2001;50(1\u20132):21\u201344.","journal-title":"Adv Drug Deliv Rev"},{"issue":"13","key":"931_CR5","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1007\/s40265-019-01171-4","volume":"79","author":"V Franco","year":"2019","unstructured":"Franco V, Perucca E. Pharmacological and therapeutic properties of cannabidiol for epilepsy. Drugs. 2019;79(13):1435\u201354.","journal-title":"Drugs"},{"issue":"6","key":"931_CR6","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1007\/s40262-019-00841-6","volume":"59","author":"B Tayo","year":"2020","unstructured":"Tayo B, Taylor L, Sahebkar F, Morrison G. A phase I, open-label, parallel-group, single-dose Trial of the pharmacokinetics, safety, and tolerability of cannabidiol in subjects with mild to severe renal impairment. Clin Pharmacokinet. 2020;59(6):747\u201355.","journal-title":"Clin Pharmacokinet"},{"issue":"8","key":"931_CR7","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1007\/s40263-020-00741-5","volume":"34","author":"E Perucca","year":"2020","unstructured":"Perucca E, Bialer M. Critical aspects affecting cannabidiol oral bioavailability and metabolic elimination, and related clinical implications. CNS Drugs. 2020;34(8):795\u2013800.","journal-title":"CNS Drugs"},{"issue":"2","key":"931_CR8","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1111\/epi.16419","volume":"61","author":"J Crockett","year":"2020","unstructured":"Crockett J, Critchley D, Tayo B, Berwaerts J, Morrison G. A phase 1, randomized, pharmacokinetic trial of the effect of different meal compositions, whole milk, and alcohol on cannabidiol exposure and safety in healthy subjects. Epilepsia. 2020;61(2):267\u201377.","journal-title":"Epilepsia"},{"issue":"11","key":"931_CR9","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1007\/s40263-018-0578-5","volume":"32","author":"L Taylor","year":"2018","unstructured":"Taylor L, Gidal B, Blakey G, Tayo B, Morrison G. A Phase I, randomized, double-blind, placebo-controlled, single ascending dose, multiple dose, and food effect trial of the safety, tolerability and pharmacokinetics of highly purified cannabidiol in healthy subjects. CNS Drugs. 2018;32(11):1053\u201367.","journal-title":"CNS Drugs"},{"issue":"11","key":"931_CR10","doi-asserted-by":"crossref","first-page":"955","DOI":"10.5414\/CP202399","volume":"53","author":"M Sato","year":"2015","unstructured":"Sato M, Narukawa M. Factors affecting intrasubject variability of PK exposure: absolute oral bioavailability and acidic nature of drugs. Int J Clin Pharmacol Ther. 2015;53(11):955\u201362.","journal-title":"Int J Clin Pharmacol Ther"},{"issue":"10","key":"931_CR11","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1007\/BF02085029","volume":"37","author":"S Agurell","year":"1981","unstructured":"Agurell S, Carlsson S, Lindgren JE, Ohlsson A, Gillespie H, Hollister L. Interactions of delta 1-tetrahydrocannabinol with cannabinol and cannabidiol following oral administration in man. Assay of cannabinol and cannabidiol by mass fragmentography. Experientia. 1981;37(10):1090\u20132.","journal-title":"Experientia"},{"issue":"10","key":"931_CR12","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1111\/epi.14555","volume":"59","author":"M Bialer","year":"2018","unstructured":"Bialer M, Johannessen SI, Koepp MJ, Levy RH, Perucca E, Tomson T, et al. Progress report on new antiepileptic drugs: a summary of the fourteenth Eilat conference on new antiepileptic drugs and devices (EILAT XIV). II. Drugs in more advanced clinical development. Epilepsia. 2018;59(10):1842\u201366.","journal-title":"Epilepsia."},{"issue":"4","key":"931_CR13","doi-asserted-by":"crossref","first-page":"327","DOI":"10.2165\/00003088-200342040-00003","volume":"42","author":"F Grotenhermen","year":"2003","unstructured":"Grotenhermen F. Pharmacokinetics and pharmacodynamics of cannabinoids. Clin Pharmacokinet. 2003;42(4):327\u201360.","journal-title":"Clin Pharmacokinet"},{"key":"931_CR14","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.3389\/fphar.2018.01365","volume":"9","author":"SA Millar","year":"2018","unstructured":"Millar SA, Stone NL, Yates AS, O'Sullivan SE. A systematic review on the pharmacokinetics of Cannabidiol in humans. Front Pharmacol. 2018;9:1365.","journal-title":"Front Pharmacol"},{"issue":"2","key":"931_CR15","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1002\/bms.1200130206","volume":"13","author":"A Ohlsson","year":"1986","unstructured":"Ohlsson A, Lindgren JE, Andersson S, Agurell S, Gillespie H, Hollister LE. Single-dose kinetics of deuterium-labelled cannabidiol in man after smoking and intravenous administration. Biomed Environ Mass Spectrom. 1986;13(2):77\u201383.","journal-title":"Biomed Environ Mass Spectrom"},{"issue":"3","key":"931_CR16","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1038\/clpt.1980.181","volume":"28","author":"A Ohlsson","year":"1980","unstructured":"Ohlsson A, Lindgren JE, Wahlen A, Agurell S, Hollister LE, Gillespie HK. Plasma delta-9 tetrahydrocannabinol concentrations and clinical effects after oral and intravenous administration and smoking. Clin Pharmacol Ther. 1980;28(3):409\u201316.","journal-title":"Clin Pharmacol Ther"},{"issue":"11","key":"931_CR17","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1111\/j.2042-7158.1974.tb09207.x","volume":"26","author":"M Widman","year":"1974","unstructured":"Widman M, Agurell S, Ehrnebo M, Jones G. Binding of (+)- and (minus)-delta-1-tetrahydrocannabinols and (minus)-7-hydroxy-delta-1-tetrahydrocannabinol to blood cells and plasma proteins in man. J Pharm Pharmacol. 1974;26(11):914\u20136.","journal-title":"J Pharm Pharmacol"},{"key":"931_CR18","unstructured":"Derendorf H, Schmidt S. Rowland and Tozer's Clinical Pharmacokinetics and Pharmacodynamics, 5th ed, Wolters Kluwer, Philadelphia, 2020, pp.134\u20137, 204\u201312 and 777\u20139"},{"issue":"4","key":"931_CR19","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1002\/cpt1975184377","volume":"18","author":"GR Wilkinson","year":"1975","unstructured":"Wilkinson GR, Shand DG. Commentary: a physiological approach to hepatic drug clearance. Clin Pharmacol Ther. 1975;18(4):377\u201390.","journal-title":"Clin Pharmacol Ther"},{"issue":"3","key":"931_CR20","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1097\/ADM.0000000000000118","volume":"9","author":"AF Manini","year":"2015","unstructured":"Manini AF, Yiannoulos G, Bergamaschi MM, Hernandez S, Olmedo R, Barnes AJ, et al. Safety and pharmacokinetics of oral cannabidiol when administered concomitantly with intravenous fentanyl in humans. J Addict Med. 2015;9(3):204\u201310.","journal-title":"J Addict Med"},{"issue":"8","key":"931_CR21","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1002\/jcph.1412","volume":"59","author":"L Taylor","year":"2019","unstructured":"Taylor L, Crockett J, Tayo B, Morrison G. A Phase 1, open-label, parallel-group, single-dose trial of the pharmacokinetics and safety of cannabidiol (CBD) in subjects with mild to severe hepatic impairment. J Clin Pharmacol. 2019;59(8):1110\u20139.","journal-title":"J Clin Pharmacol"},{"issue":"8","key":"931_CR22","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1002\/cpdd.665","volume":"8","author":"G Morrison","year":"2019","unstructured":"Morrison G, Crockett J, Blakey G, Sommerville K. A Phase 1, open-label, pharmacokinetic trial to investigate possible drug-drug interactions between clobazam, stiripentol, or valproate and cannabidiol in healthy subjects. Clin Pharmacol Drug Dev. 2019;8(8):1009\u2013311.","journal-title":"Clin Pharmacol Drug Dev"},{"key":"931_CR23","unstructured":"Whalley BJ, Stott C, Gray RA, Jones NA. The human metabolite of cannabidiol, 7-hydroxy-cannabidiol, but not 7-carboxy-cannabidiol, is anticonvulsant in the maximal electroshock threshold test (MEST) in mouse [abstract]. American Epilepsy Society Annual Meeting, 1\u20135 December 2017, Washington, DC. https:\/\/www.aesnet.org\/meetings_events\/annual_meeting_abstracts\/view\/381222. Accessed 30 May 2020."},{"issue":"1\u20132","key":"931_CR24","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/S0169-409X(01)00148-X","volume":"50","author":"GA Edwards","year":"2001","unstructured":"Edwards GA, Porter CJ, Caliph SM, Khoo SM, Charman WN. Animal models for the study of intestinal lymphatic drug transport. Adv Drug Deliv Rev. 2001;50(1\u20132):45\u201360.","journal-title":"Adv Drug Deliv Rev"},{"issue":"5","key":"931_CR25","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1016\/j.ejps.2005.07.011","volume":"26","author":"P Gershkovich","year":"2005","unstructured":"Gershkovich P, Hoffman A. Uptake of lipophilic drugs by plasma derived isolated chylomicrons: linear correlation with intestinal lymphatic bioavailability. Eur J Pharm Sci. 2005;26(5):394\u2013404.","journal-title":"Eur J Pharm Sci"},{"issue":"2","key":"931_CR26","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/0169-409X(95)00105-G","volume":"19","author":"WN Charman","year":"1996","unstructured":"Charman WN, Porter CJH. Lipophilic prodrugs designed for intestinal lymphatic transport. Adv Drug Deliv Rev. 1996;19(2):149\u201369.","journal-title":"Adv Drug Deliv Rev"},{"issue":"1s","key":"931_CR27","doi-asserted-by":"crossref","first-page":"254s","DOI":"10.18433\/jpps30217","volume":"21","author":"DR Brocks","year":"2018","unstructured":"Brocks DR, Davies NM. Lymphatic drug absorption via the enterocytes: pharmacokinetic simulation, modeling, and considerations for optimal drug development. J Pharm Pharm Sci. 2018;21(1s):254s\u2013s270270.","journal-title":"J Pharm Pharm Sci"},{"key":"931_CR28","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.jconrel.2018.07.022","volume":"286","author":"JB Lee","year":"2018","unstructured":"Lee JB, Zgair A, Malec J, Kim TH, Kim MG, Ali J, et al. Lipophilic activated ester prodrug approach for drug delivery to the intestinal lymphatic system. J Control Release. 2018;286:10\u20139.","journal-title":"J Control Release"},{"issue":"8","key":"931_CR29","first-page":"3448","volume":"8","author":"A Zgair","year":"2016","unstructured":"Zgair A, Wong JC, Lee JB, Mistry J, Sivak O, Wasan KM, et al. Dietary fats and pharmaceutical lipid excipients increase systemic exposure to orally administered cannabis and cannabis-based medicines. Am J Transl Res. 2016;8(8):3448\u2013599.","journal-title":"Am J Transl Res"},{"issue":"6","key":"931_CR30","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1016\/j.addr.2007.09.007","volume":"60","author":"NL Trevaskis","year":"2008","unstructured":"Trevaskis NL, Charman WN, Porter CJ. Lipid-based delivery systems and intestinal lymphatic drug transport: a mechanistic update. Adv Drug Deliv Rev. 2008;60(6):702\u201316.","journal-title":"Adv Drug Deliv Rev"},{"issue":"1","key":"931_CR31","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1211\/jpp.61.01.0005","volume":"61","author":"P Gershkovich","year":"2009","unstructured":"Gershkovich P, Fanous J, Qadri B, Yacovan A, Amselem S, Hoffman A. The role of molecular physicochemical properties and apolipoproteins in association of drugs with triglyceride-rich lipoproteins: in-silico prediction of uptake by chylomicrons. J Pharm Pharmacol. 2009;61(1):31\u20139.","journal-title":"J Pharm Pharmacol"},{"issue":"11","key":"931_CR32","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1038\/nrd4608","volume":"14","author":"NL Trevaskis","year":"2015","unstructured":"Trevaskis NL, Kaminskas LM, Porter CJ. From sewer to saviour: targeting the lymphatic system to promote drug exposure and activity. Nat Rev Drug Discov. 2015;14(11):781\u2013803.","journal-title":"Nat Rev Drug Discov"},{"issue":"1","key":"931_CR33","doi-asserted-by":"crossref","first-page":"14542","DOI":"10.1038\/s41598-017-15026-z","volume":"7","author":"A Zgair","year":"2017","unstructured":"Zgair A, Lee JB, Wong JCM, Taha DA, Aram J, Di Virgilio D, et al. Oral administration of cannabis with lipids leads to high levels of cannabinoids in the intestinal lymphatic system and prominent immunomodulation. Sci Rep. 2017;7(1):14542.","journal-title":"Sci Rep"},{"issue":"18","key":"931_CR34","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1007\/BF01483589","volume":"54","author":"HJ Horst","year":"1976","unstructured":"Horst HJ, Holtje WJ, Dennis M, Coert A, Geelen J, Voigt KD. Lymphatic absorption and metabolism of orally administered testosterone undecanoate in man. Klin Wochenschr. 1976;54(18):875\u20139.","journal-title":"Klin Wochenschr"},{"issue":"8","key":"931_CR35","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1111\/epi.16093","volume":"60","author":"AK Birnbaum","year":"2019","unstructured":"Birnbaum AK, Karanam A, Marino SE, Barkley CM, Remmel RP, Roslawski M, et al. Food effect on pharmacokinetics of cannabidiol oral capsules in adult patients with refractory epilepsy. Epilepsia. 2019;60(8):1586\u201392.","journal-title":"Epilepsia"},{"issue":"6","key":"931_CR36","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1007\/s11095-009-9860-z","volume":"26","author":"NL Trevaskis","year":"2009","unstructured":"Trevaskis NL, Shackleford DM, Charman WN, Edwards GA, Gardin A, Appel-Dingemanse S, et al. Intestinal lymphatic transport enhances the post-prandial oral bioavailability of a novel cannabinoid receptor agonist via avoidance of first-pass metabolism. Pharm Res. 2009;26(6):1486\u201395.","journal-title":"Pharm Res"},{"key":"931_CR37","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1111\/epi.16597","volume":"1","author":"R Odi","year":"2020","unstructured":"Odi R, Bibi D, Wager T, Bialer M. A perspective on the physicochemical and biopharmaceutic properties of marketed antiepileptic drugs\u2014from phenobarbital to cenobamate and beyond. Epilepsia. 2020. https:\/\/doi.org\/10.1111\/epi.16597","journal-title":"Epilepsia"},{"issue":"1","key":"931_CR38","first-page":"39","volume":"6","author":"TT Kararli","year":"1989","unstructured":"Kararli TT. Gastrointestinal absorption of drugs. Crit Rev Ther Drug Carrier Syst. 1989;6(1):39\u201386.","journal-title":"Crit Rev Ther Drug Carrier Syst"},{"issue":"9","key":"931_CR39","doi-asserted-by":"crossref","first-page":"753","DOI":"10.2174\/138920021609151201113537","volume":"16","author":"T Nakanishi","year":"2015","unstructured":"Nakanishi T, Tamai I. Interaction of drug or food with drug transporters in intestine and liver. Curr Drug Metab. 2015;16(9):753\u201364.","journal-title":"Curr Drug Metab"},{"issue":"1","key":"931_CR40","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.cld.2016.08.001","volume":"21","author":"OA Almazroo","year":"2017","unstructured":"Almazroo OA, Miah MK, Venkataramanan R. Drug metabolism in the liver. Clin Liver Dis. 2017;21(1):1\u201320.","journal-title":"Clin Liver Dis"},{"key":"931_CR41","doi-asserted-by":"crossref","first-page":"458","DOI":"10.3389\/fphys.2020.00458","volume":"11","author":"NL Trevaskis","year":"2020","unstructured":"Trevaskis NL, Lee G, Escott A, Phang KL, Hong J, Cao E, et al. Intestinal lymph flow, and lipid and drug transport scale allometrically from pre-clinical species to humans. Front Physiol. 2020;11:458.","journal-title":"Front Physiol"},{"issue":"44","key":"931_CR42","doi-asserted-by":"crossref","first-page":"13700","DOI":"10.1002\/anie.201604207","volume":"55","author":"L Hu","year":"2016","unstructured":"Hu L, Quach T, Han S, Lim SF, Yadav P, Senyschyn D, et al. Glyceride-mimetic prodrugs incorporating self-immolative spacers promote lymphatic transport, avoid first-pass metabolism, and enhance oral bioavailability. Angew Chem Int Ed Engl. 2016;55(44):13700\u20135.","journal-title":"Angew Chem Int Ed Engl"},{"issue":"2","key":"931_CR43","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/BF03189840","volume":"11","author":"U Tauber","year":"1986","unstructured":"Tauber U, Schroder K, Dusterberg B, Matthes H. Absolute bioavailability of testosterone after oral administration of testosterone-undecanoate and testosterone. Eur J Drug Metab Pharmacokinet. 1986;11(2):145\u20139.","journal-title":"Eur J Drug Metab Pharmacokinet"},{"key":"931_CR44","doi-asserted-by":"crossref","first-page":"7291","DOI":"10.2147\/IJN.S214883","volume":"14","author":"H Liao","year":"2019","unstructured":"Liao H, Gao Y, Lian C, Zhang Y, Wang B, Yang Y, et al. Oral absorption and lymphatic transport of baicalein following drug-phospholipid complex incorporation in self-microemulsifying drug delivery systems. Int J Nanomed. 2019;14:7291\u2013306.","journal-title":"Int J Nanomed"},{"issue":"1","key":"931_CR45","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1080\/10717544.2019.1686086","volume":"26","author":"Y Tong","year":"2019","unstructured":"Tong Y, Zhang Q, Shi W, Wang J. Mechanisms of oral absorption improvement for insoluble drugs by the combination of phospholipid complex and SNEDDS. Drug Deliv. 2019;26(1):1155\u201366.","journal-title":"Drug Deliv"},{"issue":"4","key":"931_CR46","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1007\/BF03190223","volume":"15","author":"N Barzaghi","year":"1990","unstructured":"Barzaghi N, Crema F, Gatti G, Pifferi G, Perucca E. Pharmacokinetic studies on IdB 1016, a silybin- phosphatidylcholine complex, in healthy human subjects. Eur J Drug Metab Pharmacokinet. 1990;15(4):333\u20138.","journal-title":"Eur J Drug Metab Pharmacokinet"},{"issue":"7","key":"931_CR47","first-page":"964","volume":"42","author":"R Schandalik","year":"1992","unstructured":"Schandalik R, Gatti G, Perucca E. Pharmacokinetics of silybin in bile following administration of silipide and silymarin in cholecystectomy patients. Arzneimittelforschung. 1992;42(7):964\u20138.","journal-title":"Arzneimittelforschung"},{"issue":"5","key":"931_CR48","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1016\/j.xphs.2017.12.020","volume":"107","author":"J Atsmon","year":"2018","unstructured":"Atsmon J, Cherniakov I, Izgelov D, Hoffman A, Domb AJ, Deutsch L, et al. PTL401, a new formulation based on pro-nano dispersion technology, improves oral cannabinoids bioavailability in healthy volunteers. J Pharm Sci. 2018;107(5):1423\u20139.","journal-title":"J Pharm Sci"},{"key":"931_CR49","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejpb.2020.06.021","author":"D Izgelov","year":"2020","unstructured":"Izgelov D, Davidson E, Barasch D, Regev A, Domb AJ, Hoffman A. Pharmacokinetic investigation of synthetic cannabidiol oral formulations in healthy volunteers. Eur J Pharm Biopharm. 2020. https:\/\/doi.org\/10.1016\/j.ejpb.2020.06.021.","journal-title":"Eur J Pharm Biopharm."},{"issue":"16","key":"931_CR50","doi-asserted-by":"crossref","first-page":"2967","DOI":"10.3390\/molecules24162967","volume":"24","author":"K Knaub","year":"2019","unstructured":"Knaub K, Sartorius T, Dharsono T, Wacker R, Wilhelm M, Schon C. A novel self-emulsifying drug delivery system (SEDDS) based on VESIsorb(R) formulation technology improving the oral bioavailability of cannabidiol in healthy subjects. Molecules. 2019;24(16):2967.","journal-title":"Molecules"},{"issue":"1","key":"931_CR51","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1208\/s12249-018-1239-1","volume":"20","author":"NK Swarnakar","year":"2018","unstructured":"Swarnakar NK, Venkatesan N, Betageri G. Critical in vitro characterization methods of lipid-based formulations for oral delivery: a comprehensive review. AAPS PharmSciTech. 2018;20(1):16.","journal-title":"AAPS PharmSciTech"},{"key":"931_CR52","doi-asserted-by":"crossref","first-page":"105313","DOI":"10.1016\/j.ejps.2020.105313","volume":"148","author":"D Izgelov","year":"2020","unstructured":"Izgelov D, Domb AJ, Hoffman A. The effect of piperine on oral absorption of cannabidiol following acute vs. chronic administration. Eur J Pharm Sci. 2020;148:105313.","journal-title":"Eur J Pharm Sci."},{"key":"931_CR53","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jconrel.2017.09.011","volume":"266","author":"I Cherniakov","year":"2017","unstructured":"Cherniakov I, Izgelov D, Barasch D, Davidson E, Domb AJ, Hoffman A. Piperine-pro-nanolipospheres as a novel oral delivery system of cannabinoids: pharmacokinetic evaluation in healthy volunteers in comparison to buccal spray administration. J Control Release. 2017;266:1\u20137.","journal-title":"J Control Release"},{"issue":"8","key":"931_CR54","doi-asserted-by":"crossref","first-page":"e199144","DOI":"10.1001\/jamanetworkopen.2019.9144","volume":"2","author":"CM Warren","year":"2019","unstructured":"Warren CM, Chadha AS, Sicherer SH, Jiang J, Gupta RS. Prevalence and severity of sesame allergy in the United States. JAMA Netw Open. 2019;2(8):e199144.","journal-title":"JAMA Netw Open"}],"container-title":["Clinical Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-020-00931-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40262-020-00931-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-020-00931-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,11]],"date-time":"2021-08-11T23:14:16Z","timestamp":1628723656000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40262-020-00931-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,12]]},"references-count":54,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["931"],"URL":"https:\/\/doi.org\/10.1007\/s40262-020-00931-w","relation":{},"ISSN":["0312-5963","1179-1926"],"issn-type":[{"value":"0312-5963","type":"print"},{"value":"1179-1926","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,8,12]]},"assertion":[{"value":"12 August 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors confirm they have read the Journal\u2019s position on issues involved in ethical publication and affirm that this report is consistent with those guidelines.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This work was not supported by any funding source.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Valentina Franco received consultancy fees from GW Pharma. PG has no conflicts of interest to disclose. EP received speaker\u2019s or consultancy fees from Amicus Therapeutics, Arvelle, Biogen, Eisai, GW Pharma, Intas Pharmaceuticals, Laboratorios Bag\u00f2, Sanofi, Sun Pharma, UCB Pharma and Xenon Pharma. MB received speaker\u2019s or consultancy fees from Alkaloid, Boehringer Ingelheim, Medison and US\u00a0WorldMeds.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}